Introduction
premenopausal, not pregnant, breastfeeding, or taking exogenous hormones during the preceding 3 months, and had never had chemoAn immunological variant of luteinizing hormone (v-LH) has therapy, hormonal therapy, or radiation to the pelvis. From this study, been described and attributed to two point mutations (Trp8Arg there were 94 cases who participated and had plasma specimens still and Ile15Thr) in gene coding the LHβ-subunit (Pettersson available. In both studies, we selected control women from the et al., 1992; Furui et al., 1994; Nilsson et al., 1998) . The general population using annually published lists of residents of carrier frequency of the v-LHβ allele varies widely from 0%
Massachusetts. We similarly restricted control selection to women to Ͼ50%, appearing to be less common among populations Ͻ50 years who were not pregnant, breastfeeding, or using oral from Asia and more common among populations from Northern contraceptives, and were matched controls to cases by age and Europe (Nilsson et al., 1997 (Nilsson et al., , 1998 . Whether the variant may precinct of residence. We had the additional requirements that the affect ovarian (or testicular) function or risk for hormonallycontrols should not have a family history of ovarian cancer or should not have breast cancer or BCIS. Women were randomly sampled to related diseases has not been fully investigated. In particular, match the age and residency distribution of the FOC or BCIS cases groups. Significant differences in Table II included: lower LH as previously described (Cramer et al., 1994; Bohlke et al., 1998). concentrations for FOC cases compared with FOC controls From both studies, plasma was available on 154 subjects.
(P Ͻ 0.01) previously described (Cramer et al., 1994) and one among the BCIS controls. None of these differences as the standard. Intra-and interassay coefficients of variation were were statistically significant; nor was there any significant less than 10 and 15% respectively, for all three assays. Between the difference in the frequency of the v-LH carriers by white two study periods the standard for FSH changed from the first to the versus non-white, Jewish versus non-Jewish, or ever versus second IRP leading to lower measured FSH in the second compared never married comparisons. Overall, the frequency of to the first study.
heterozygosity for v-LH was 17.6% and the frequency of Plasma that had been banked from the studies was retrieved and homozygosity for v-LH was 0.9% in the entire study popusent to one of the authors (I.T.H.) for determination of v-LH status lation.
as previously described (Pettersson et al., 1992) . LH genotypes to wild types in all controls and in all subjects combined.
of monoclonal antibodies (mAb). The reference method (assay 2)
Attention is focused on those characteristics which differed used two LHβ-specific mAB that recognized wild type and v-LH significantly (P ഛ 0.05) or were of borderline statistical with similar stoichiometries. In the other assay (assay 1), one of the significance (P ഛ 0.10). LH variant carriers and homozygotes mAB used recognized only the intact LHα/β dimer, but not v-LH.
were less likely to report menstrual weight gain (P Ͻ 0.05,
The ratio of LH values measured by assay 1/assay 2 allowed among all controls and all subjects), to have a history of classification of the samples into three categories: (i) Ͼ0.9 (normal ratio), the subject had two normal LHβ alleles; (ii) 0.2-0.9 (low ovarian cysts (P ϭ 0.08, among all subjects), to be smokers ratio), the subject was heterozygous for the mutant LHβ gene;
(P ϭ 0.05 among all controls and P ϭ 0.06 among all (iii) Ͻ0.15 ('zero' ratio), the subject was homozygous for the mutant subjects), and to have a family history of prostate cancer LH gene. The intra-and interassay variations of assay 1 and 2 were (P ϭ 0.09, among all controls). The observation that v-LH v-LH carriers to be nulliparous and the average number of pregnancies was 2.06 for v-LH carriers and 2.11 for wild types (not significant). Presence of the LH variant had no significant Results influence on whether cycles were likely to be irregular or Table I shows the characteristics of the study groups. associated with moderate or severe menstrual pain and whether Subjects from the BCIS study were older than subjects from subjects had endometriosis, diabetes, or a family history of the FOC study (P Ͻ 0.05), and BCIS controls were more breast cancer (data not shown). likely to be parous compared with BCIS cases (P Ͻ 0.05). types did not differ significantly in age at menarche, cycle 0.15 for FSH, 0.03 for LH and 0.15 for oestradiol. Thus, women who were heterozygotes for v-LH had significantly length, or BMI. Because any hormonal differences by LH variant status may be confounded by age and assay differences higher early follicular phase LH concentrations by the assays done in Boston. Two of the women who were homozygous between studies pointed out above in connection with Table  II , we used generalized linear modelling applied to all subjects for v-LH had normal early follicular phase hormone concentrations, while the third had very low hormone concentrations to adjust for study, case or control status, age, smoking, and body mass index. The P values adjusted for those variables with FSH of 0.47 IU/l, LH of 0.10 IU/l, and an oestradiol concentration of 18.8 pg/ml. and associated with v-LH heterozygosity as a predictor were et al., 1992 et al., ) and genetically in 1994 et al., (Furui et al., 1994 , there necessary before these associations are considered null. has been increasing interest in a variant form of LH as it might
We found the overall frequency of heterozygosity for v-LH relate to ovarian function and hormonally-related diseases.
allele to be 17.6% which matches closely previous estimates Because v-LH is more common among populations that are of the frequency of v-LH carriers in Northern European also at higher risk for ovarian and breast cancers, we thought populations (Nilsson et al., 1997) . The high frequency of the it reasonable to consider the relationship of these disorders to variant has been interpreted to indicate that v-LH probably the variant. Using banked specimens from previously comdoesn't impact on male or female fertility but published results pleted studies, we determined the v-LH status of women with are discrepant. A study of Japanese women suggested that the a family history of ovarian cancer and women with BCIS.
variant does occur with higher frequency in women who have Studying these groups, rather than breast or ovarian cancer ovulatory problems (Takahaski et al., 1999) , while another patients themselves, allowed us to assess the impact of the study (Ramanujam et al., 2000) found no association between variant on basal hormone concentrations which would have male infertility and LH variants. Among the combined controls been altered by ovarian or breast cancer treatment. In our in our study, who were selected from the general population study, we found no evidence that v-LH was more common rather than infertility clinics, we found a higher frequency among women with a family history of ovarian cancer or with BCIS compared to controls. While this suggests that v-LH is of self-reported delay-to-conception associated with v-LH.
Medical records were not available to clarify the nature of the family history of ovarian cancer or BCIS, we found no evidence of a greater frequency of v-LH that might suggest an association fertility problems in women with v-LH. Overall, among v-LH with ovarian or breast cancer. However, our study suggests carriers or homozygotes, the proportion of nulliparous women that v-LH may impact on ovarian function. In particular, was not significantly increased suggesting that v-LH may be women who possess v-LH may have sub-fertility, especially related to subfertility rather than sterility. Of potential interest those with normal or below normal BMI. Further studies of is the fact that the 16 subjects with v-LH who reported the effect of v-LH on ovarian (and testicular) function may be infertility had apparently lower BMI (23.3 kg/m 2 ) compared of value in sorting out the long-appreciated link between body to the BMI (25.3 kg/m 2 ) of those women with v-LH who did mass and fertility. not report infertility (not significant). Although this difference was not significant, it contrasts with nearly identical BMI in the women with and without infertility who were wild type,
